LL-37 vs Thymosin Alpha-1: Direct Antimicrobial Action Against Immune Modulation

Both molecules belong to immunology, but they operate at opposite ends of the immune system. One, LL-37, carries a strong positive charge and engages microbial membranes directly. The other, Thymosin Alpha-1, is acidic, comes from the thymus, and is studied for how it shapes T-cell maturation and Toll-like receptor signalling. In other words: effector chemistry versus regulatory signalling. Which one you want depends entirely on whether your assay reads out direct antimicrobial or membrane effects, or the shaping of an immune response.

Both are supplied as freeze-dried powder with a certificate matched to the lot — Thymosin Alpha-1 in 20, 10 and 5 mg vials, LL-37 in 10 and 5 mg vials. Thymosin Alpha-1 is catalogued with the immune peptides and LL-37 with the anti-inflammatory peptides. Both are research chemicals for in-vitro and preclinical laboratory work only and are never intended for people.

An effector molecule beside a regulatory one

LL-37 is an effector molecule. Keratinocytes, epithelial cells and neutrophils synthesise its precursor hCAP18, and proteinase 3 cleaves it at sites of injury or infection to release the mature 37-residue peptide. Its function follows from its shape: an amphipathic, cationic helix that embeds itself in the negatively charged membranes of bacteria, and the mechanism most often described is loss of membrane integrity. That is chemistry acting on a target, not a message being relayed.

There is also a second and less tidy strand to its literature. The peptide binds lipopolysaccharide, influences chemotaxis, and has been reported to modulate receptor-driven immune signalling — which places it in the regulatory category too. This dual character is precisely what makes LL-37 difficult to study without ambiguity, and why experiments with it require more controls than usual.

Thymosin Alpha-1 is purely regulatory. It has no antimicrobial action of any kind; the mechanisms reported for it are about how immune cells behave — the differentiation and maturation of T cells, and modulation of Toll-like receptor signalling, with TLR2 and TLR9 featuring most often in the published work. Acidic and with little defined secondary structure, it is the mirror image of LL-37's charged helix in every way that matters practically.

How much evidence exists, and of what kind

These two occupy different levels of the evidence hierarchy, and it is worth being precise about the difference.

For LL-37, the record is laboratory-based: minimum inhibitory concentration and susceptibility testing against a range of bacteria, work on disrupting biofilms, epithelial and wound repair models, and cell studies of LPS neutralisation and chemotaxis. Nothing containing LL-37 has been approved as a product, and human data barely exist. By any strict definition it is still a research molecule.

Thymosin Alpha-1 is unusual among the peptides we list in having a genuine clinical track record. Several countries outside the United States have approved a synthetic version for hepatitis B, hepatitis C and use as a vaccine adjuvant, and certain editions of the WHO essential medicines list have included it. Its literature therefore includes controlled trials in humans in addition to the usual rodent and cell work. Two things must be said about that. Those trials used pharmaceutical-grade material given under medical supervision, and they tell you nothing whatsoever about research-grade powder ordered as a reagent. The product we sell is not that regulated article and is not supplied for any use in humans. For a closer look at each body of evidence, see our Thymosin Alpha-1 primer and our LL-37 background article.

Matching the peptide to the research question

Choose LL-37 for membrane and antimicrobial work

If your endpoint is fungal or bacterial growth inhibition, permeabilisation of membranes, biofilm disruption or neutralisation of LPS, LL-37 is the only one of the two that participates — Thymosin Alpha-1 does none of these things and would function as a negative control rather than a comparator. LL-37 is also the appropriate tool for broader questions about host-defence peptide chemistry, since it is the single human cathelicidin in existence.

Choose Thymosin Alpha-1 for immune-modulation endpoints

If you are measuring T-cell maturation markers, cytokine responses to a defined stimulus, Toll-like receptor activation, or adjuvant effects in an animal model, Thymosin Alpha-1 is the peptide the published literature actually used. It is also the easier choice for extended experiments, purely because keeping it stably and reproducibly dissolved presents no difficulty. Laboratories working on the thymic peptide family as a whole frequently include it alongside with thymalin, a thymic-extract preparation, as a family reference.

Use both when you are dissecting host defence

An improvement in an infection model can arise either from attacking the pathogen or from altering the host's response. Because these two peptides correspond almost exactly to those two possibilities, testing them as separate arms is a straightforward way to distinguish them — remembering that LL-37 is not a purely effector molecule, so its immunomodulatory activity needs controls of its own. Both are available in the same 10 and 5 mg formats, which makes preparing molar-matched arms simple, and Thymosin Alpha-1 is additionally offered as a pre-mixed nasal solution if you want to compare formats.

Handling and storage: where they differ most

Thymosin Alpha-1 asks very little of the operator. It is acidic, dissolves readily in water, has little defined structure and shows almost no tendency to aggregate, so the standard routine is enough: store the sealed freeze-dried vial in the freezer, let it warm to room temperature before the stopper is pierced so that no moisture condenses on the chilled powder, introduce diluent along the inside wall, let it go into solution without shaking, and divide it into single-use portions.

LL-37, by contrast, is one of the more difficult peptides we stock and deserves its own handling protocol, for three reasons. Because it is so strongly cationic, it adheres to glass and to ordinary polypropylene, so a dilute working solution can lose a large share of its peptide to the tube before it ever reaches the assay — the usual countermeasures are low-binding labware and, where the assay tolerates it, a carrier protein. Its antimicrobial potency also depends heavily on ionic strength and on the presence of serum: a value measured in low-salt buffer will not be reproduced at physiological salt concentration or in serum-supplemented medium, so never assume a result carries across conditions. And because the same amphipathic helix that opens bacterial membranes can also affect mammalian ones at higher concentrations, haemolysis and cytotoxicity controls should be designed in from the outset, not added afterwards.

Concentration is bench arithmetic and not a usage recommendation: adding 2 mL of diluent to a 5 mg vial gives 2.5 mg/mL — 2,500 mcg/mL — so 0.1 mL contains 250 mcg. Since 4493.33 g/mol and 3108.30 g/mol are very different weights, equal mass concentrations are not equal molarities, so comparative arms have to be built on a molar basis. The reconstitution and storage guides cover the rest.

Purity, identity and certificate checks

Request the lot-specific certificate for each vial and check HPLC purity against a chromatogram you can examine, a measured mass matching theory — 3108.30 g/mol for Thymosin Alpha-1, 4493.33 g/mol for LL-37 — and a lot number matching the vial. Each peptide has its own particular issue. LL-37 is long, highly charged and genuinely difficult to synthesise, which its price reflects; deletion sequences are the impurity to look out for, and because it binds LPS directly, endotoxin content is a legitimate question for any immune-signalling experiment in which LPS contamination would corrupt the reading. Thymosin Alpha-1's key chemical feature is its N-terminal acetyl group; the des-acetyl form weighs 42 Da less and counts as a different molecule wherever published comparisons are concerned, so acetylation should be confirmed rather than assumed. Our COA guide describes what a complete document includes.

Regulatory position

Both are supplied purely as research chemicals for laboratory use and not for human consumption. There is no approved LL-37 product in any country. Thymosin Alpha-1 does have prescription-medicine status in certain countries outside the United States, but that status attaches to a regulated pharmaceutical article rather than to research-grade powder. Our immune research overview gives the broader picture.